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Abstract
Background: Four clinical trials have shown that oral and topical pre-exposure prophylaxis (PrEP) based on tenofovir may
be effective in preventing HIV transmission. The expected reduction in HIV transmission and the projected prevalence of
drug resistance due to PrEP use vary significantly across modeling studies as a result of the broad spectrum of assumptions
employed. Our goal is to quantify the influence of drug resistance assumptions on the predicted population-level impact of
PrEP.
Methods: All modeling studies which evaluate the impact of oral or topical PrEP are reviewed and key assumptions
regarding mechanisms of generation and spread of drug-resistant HIV are identified. A dynamic model of the HIV epidemic
is developed to assess and compare the impact of oral PrEP using resistance assumptions extracted from published studies.
The benefits and risks associated with ten years of PrEP use are evaluated under identical epidemic, behavioral and
intervention conditions in terms of cumulative fractions of new HIV infections prevented, resistance prevalence among
those infected with HIV, and fractions of infections in which resistance is transmitted.
Results: Published models demonstrate enormous variability in resistance-generating assumptions and uncertainty in
parameter values. Depending on which resistance parameterization is used, a resistance prevalence between 2% and 44%
may be expected if 50% efficacious oral PrEP is used consistently by 50% of the population over ten years. We estimated
that resistance may be responsible for up to a 10% reduction or up to a 30% contribution to the fraction of prevented
infections predicted in different studies.
Conclusions: Resistance assumptions used in published studies have a strong influence on the projected impact of PrEP.
Modelers and virologists should collaborate toward clarifying the set of resistance assumptions biologically relevant to the
PrEP products which are already in use or soon to be added to the arsenal against HIV.
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Introduction
Several randomized clinical trials demonstrated that if used
adequately, pre-exposure prophylaxis (PrEP) products in the form
of daily pills (oral PrEP) or topical gels (vaginal microbicides) could
be partially effective in preventing HIV acquisition for men who
have sex with men [1], heterosexual men and women [2,3], and
serodiscordent couples [4]. Although these encouraging results
were not confirmed in two other trials [5,6], Truvada (emtricita-
bine/tenofovir disoproxil fumarate) became the first drug
approved for PrEP use in US [7]. Guidelines for the safe use of
PrEP by MSM and heterosexually active adults have recently been
published by the Center for Diseases Control (CDC) and the
Southern African HIV Clinicians Society [8–10]. PrEP products
could therefore add to the HIV prevention options available to
both state and local health officials, who then decide how best to
allocate resources.
Mathematical models are increasingly being used to assess the
potential public health impact of oral or topical PrEP interventions
for specific regions or populations in order to better understand
when they can be most useful [11–30]. One of the greatest
concerns for the successful addition of antiretroviral (ARV) based
PrEP to HIV prevention programs is that infected individuals who
use PrEP, because they are either unaware of their serostatus or
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become HIV-positive after starting to use the product, may
acquire drug resistance (ADR) and thus increase the risk of
transmitting drug resistance (TDR). Currently, little resistance was
reported in the completed clinical trials, which may be at least
partly because the trials were of short duration and because PrEP
users were frequently monitored and taken off treatment soon after
seroconversion, probably much sooner than would likely happen
in real life.
Of all modeling studies assessing the effectiveness of PrEP
published before 2012 [11–30], only a few discussed the possible
spread of drug resistance and its influence on the success of PrEP
interventions. These mathematical models use a broad range of
assumptions and parameter values to reflect the mechanisms of
drug-resistance (e.g. the rate of emergence of drug resistance
among HIV positive individuals who use PrEP, infectiousness of
resistance carriers, rate of resistance reversion following PrEP
discontinuation, and PrEP efficacy against drug-resistant HIV
infection). In addition, modeling studies examine various PrEP
intervention scenarios in different HIV epidemics and populations,
often using study-specific indicators and time frames to assess the
benefits and risks associated with PrEP use. Therefore, differences
in the projected population-level impact of PrEP use across models
are difficult to understand, even in in-depth reviews [31].
Depending on the combination of assumptions used, some
modeling studies suggest that the emergence of drug resistance
may lead to a greater reduction in overall HIV incidence.
The HIV Modeling Consortium, which aims to help improve
scientific support for decision making by co-coordinating a wide
Figure 1. Flow diagram of the model. Simulated population is stratified in compartments by gender as men (subscript g =m) or women
(subscript g =w) and by HIV status as susceptibles (S), infected with wild HIV (I), infected with drug-resistant HIV through transmission (IR), individuals
who developed (acquired) resistance on PrEP (Ir) and AIDS (A). PrEP users (superscript p) strictly follow the prescribed daily regimen but drop out (at
rate d) if tested HIV positive. A complete description of the model including the expressions for the forces of infections (l) is presented in File S1.
doi:10.1371/journal.pone.0080927.g001
Table 1. Parameters and ranges used in the analysis.
Parameter Description Values and ranges Ref.
A. Behavioral and epidemic parameters (pre-intervention) Prior range
bw Female HIV acquisition risk per vaginal act 0.0019–0.0046 [38]
bm Male HIV acquisition risk per vaginal act (50–100%) of bw assumed [38]
1/m Average time to remain sexually active 35 years [39,40]
dr, d HIV-related mortality rates of people infected with resistant and wild-type HIV 8.3%–14.3% [41,42]
nw, nm Average number of sexual acts per year for women and men 60–100 [43,44]
rw, rm Average number of sexual partners per year for women and men 0.5–1.5 [44–45]
c Rate of condom use in general population as a fraction of sex acts in which
a condom is used
20–60% [43,44]
ac Condom efficacy per sex act 0.8–0.95 [46]
B. Calibrated epidemic data
Pw Initial HIV-prevalence (women) 20% [36]
Pm Initial HIV-prevalence (men) 15% [36]
Inc Fitted HIV-incidence (total) 0.6–2.5% [37]
Pr5 Fitted HIV-prevalence in 5 years (total) 16.5%–18.5% assumed
C. Intervention parameters Baseline value
k PrEP coverage. Proportion of men and women who use PrEP. 50% assumed
k1 Initial fraction of the susceptibles using PrEP 50% assumed
aS PrEP efficacy in reducing susceptibility per act when exposed to wild-type HIV 50% assumed
ai PrEP efficacy in reducing infectiousness per act wild type when exposed to wild-type HIV 50% assumed
c PrEP adherence 100% assumed
doi:10.1371/journal.pone.0080927.t001
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range of research activities in mathematically modeling the HIV
epidemic, has acknowledged the importance of the issues related to
PrEP resistance. At a meeting organized by the consortium in
2011, mathematical modelers and virologists discussed model and
parameters assumptions required to represent the potential
emergence and spread of drug resistance due to PrEP. Participants
agreed that resistance mechanisms embedded in models should be
rigorously and systematically studied [32].
In this paper, we extend the narrative review by Baggaley et al
[31] and investigate, with a mathematical model, the independent
and combined effects of key resistance assumptions from
previously published studies on the outcomes of oral PrEP
interventions. We focus on understanding the extent to which
ignoring the development and spread of resistance influences
modeling results, under a variety of epidemic conditions. We also
identify conditions under which drug resistance may cause an
increase in the projected number of prevented infections due to
PrEP use.
Methods
Transmission model
We developed a compartmental mathematical model of HIV
transmission in a heterosexual population (age 15–49) to study the
influence of drug resistance on the impact of PrEP (Figure 1). The
individuals in the simulated population are aggregated in
compartments for men (subscript g = m) and women (subscript
g = w), by PrEP status as users (superscript p) and nonusers, and by
HIV status as susceptible (S), infected with wild-type HIV (I),
infected with drug-resistant HIV through transmission (subscript
R), individuals who developed (acquired) resistance while using
PrEP (subscript r) and AIDS (A). HIV susceptible men and women
who become sexually active join the community at constant rates,
and are selected to balance the departure rate in an uninfected
population. The rates at which men and women acquire HIV-
infection, i.e., forces of infection for different classes, are derived
from standard binomial models based on the annual number of
partners per susceptible person, the number of sex acts per
partnership, the fraction of sex acts protected by condoms, and the
HIV acquisition risk per vaginal act for men and women, which
may depend on resistance status of the infected partner at the time
of exposure (wild type vs. drug-resistant carrier). A fraction of the
initial and newly recruited population is assumed to be PrEP users.
When PrEP is used by one or both partners in a serodiscordant
contact, the acquisition risk of the susceptible partner is influenced
by the protection per sex act provided by PrEP (PrEP efficacy) as
described below. PrEP users may undergo initial and subsequent
periodic HIV testing at different frequencies. They strictly follow
the prescribed daily regimens but are removed from PrEP if tested
positive for HIV. The efficacy of PrEP is allowed to vary for
resistant infections as described in one of the next sections. A
complete description of the model is given in File S1.
PrEP efficacy and intervention coverage
The results from the concluded clinical trials suggest that when
used consistently, oral PrEP provides partial protection against
HIV acquisition and therefore reduces the susceptibility of the
users [1,3,4]. It is also theoretically plausible that infected
individuals who continue to use ARV-based PrEP will have a
reduced viral load and therefore a lower risk of transmitting HIV
to their uninfected partners. Studies of tenofovir use by HIV-
positive individuals have associated it with low-level viremia [33–
35], and support the potential role of PrEP in reducing
infectiousness incorporated in some of the published modeling
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studies. Here we assume equal reduction of susceptibility and
infectiousness due to PrEP use. The protective effect is multipli-
cative when both partners in a serodiscordant contact use PrEP.
To ensure comparability between all scenarios we assume that
50% of the sexually active men and women start using PrEP from
the moment of its introduction (instantaneous uptake) and follow
strictly the prescribed regimen (perfect adherence). The same
fraction (50%) of newly sexually active individuals is assumed to
become PrEP users. Although important when predicting the
absolute effectiveness of PrEP interventions, coverage is unlikely to
affect the relative contribution of resistance, which we investigate
(see Fig. S1 in File S1 for simulations with 25% coverage). Efforts
to limit PrEP use by HIV positive individuals are incorporated in
the intervention at introduction and are followed by periodic HIV
screening. No change in sexual behavior (frequency of sex acts,
condom use rate) due to the access to PrEP is considered. A
complete description of the intervention parameters, unrelated to
resistance, is given in Table 1, part C.
Assumption on drug resistance due to ARV PrEP
Consistent PrEP use after HIV acquisition or initiating PrEP in
already infected individuals may lead to emergence of acquired
drug resistance (ADR), which may subsequently be transmitted to
ARV-naı¨ve individuals (transmitted drug-resistance, TDR). We
reviewed 20 studies, published before 2012, which evaluated the
impact of oral or topical PrEP with dynamic mathematical models
[11–30], and focused on the studies which addressed drug
resistance due to PrEP [15,19,21,23–26]. Three of the selected
studies simulate interventions of topical PrEP [19,23,25] while the
other four investigate interventions of oral PrEP [15,21,24,26]. We
extracted the modeling and parameter assumptions regarding the
emergence, persistence and transmission of drug resistance due to
PrEP implemented in these models. Our model, which represents
oral PrEP, was designed to accommodate key resistance-related
mechanisms and assumptions used in the previous published
analyses in order to compare their influence. The list includes
assumptions regarding the efforts to restrict the access of infected
individuals to PrEP, which could be managed during real-time
interventions by:
– Restricting the opportunities of already infected individuals to
start using PrEP. Prescription rejection rate (h) represents the
actual reduction in new PrEP prescriptions issued to infected
compared to susceptible individuals. If the access to PrEP is not
controlled (h= 0), then the same proportion of infected and
susceptible people initiate PrEP. Conversely, if the access to
PrEP is under strict control (h= 1), then no infected individuals
start using PrEP;
– Removal of the HIV-positive PrEP users from PrEP as a result
of periodic HIV screening. Annual PrEP drop-rate (d)
represents the rate at which infected PrEP users stop taking
their pills. It is reciprocal to the average time to remain on
PrEP after HIV acquisition. For instance, if d= 0.5 people who
acquire HIV when on PrEP continue to take their pills for an
average of two years.
The rest of the modeling assumptions are related to the natural
history of resistance in an infected host using PrEP:
– Consistent use of oral PrEP by infected individuals leads to
emergence of drug resistance at rate r. The resistance rate is
reciprocal to the average time needed to develop resistance
while infected with HIV and using PrEP;
– Resistance carriers may be less infectious than those infected
with wild-type HIV (relative infectiousnessbr) due to the
reduced fitness of the resistant compared to wild-type HIV.
Relative infectiousness of 50% (br = 0.5) implies that it is half as
likely to acquire HIV during contact with a partner infected
with resistant HIV;
– Probabilities to acquire resistant HIV through transmission,
given that the transmission occurs, may be different for
contacts with partners infected with TDR (probabilitye1) and
ADR (probability e);
– The dominance of resistant HIV in an infected host may revert
back to wild type when PrEP is not used. The reversion rate
may be substantially slower in ARV-naı¨ve hosts with TDR
(reversion rate t1) compared to former PrEP users who
developed ADR when on PrEP (reversion ratet). For instance,
ADR may revert back over three months after PrEP use is
interrupted (t= 4), while it may take four years to lose
detectable TDR (t1 = 0.25);
– PrEP may provide reduced protection when susceptible users
are exposed to drug-resistant compared to wild-type HIV
(relative PrEP efficacy cr). A relative PrEP efficacy of 50%
(cr = 0.5) implies that PrEP is half as effective per sex act with a
partner infected with resistant HIV compared to an act with a
partner infected with wild-type HIV.
We have compiled a list of the ranges of resistance-related
parameters used in the published papers which include resistance
(see Table 2). To help interpret results across studies, we analyzed
the model outcomes using 10,000 parameter combinations,
randomly sampled from the set extracted from each study. An
aggregated parameter set (Table 2, last column), which combines
the ranges from all studies, is used when the impact of resistance
factors is evaluated in multivariate sensitivity analysis.
Epidemic settings and intervention scenarios
Demographic, behavioral and epidemic parameters were
defined and initially sampled from ranges representative of the
HIV epidemics in the Sub-Saharan region (see Table 1, part A).
Next, we identified 1,000 posterior parameter sets, reflecting
prototypical hyper endemic in southern Africa using the following
target criteria (see Table 1, part B): i) initial HIV prevalence of
15% and 20% among 15–49 years old men and women,
respectively [36]; ii) annual incidence rate between 0.6% and
2.5% [37]; iii) female incidence rate at least 30% higher than male
incidence rate[37]; and iv) the absolute difference in HIV
prevalence over five years remains below 1% (mature epidemics).
With the selected epidemic parameters we simulate: i) an HIV
epidemic without PrEP use; ii) an HIV epidemic with PrEP use
but without drug resistance due to PrEP, and iii) an HIV epidemic
with PrEP use assuming emergence of drug resistance due to
PrEP. The impact of the PrEP interventions is measured in terms
of the cumulative fraction of infections prevented (CPF), the
cumulative fraction of infections in which drug-resistant HIV is
transmitted (TRF), and the resistance prevalence (RP) among
HIV-positive individuals, all evaluated over ten years of PrEP use.
The choice of epidemic sets has little influence on the intervention
outcomes. Results from simulations in which only epidemic and
resistance parameters are varied while the other parameters
remain fixed are presented in the Supporting Information (see Fig.
S2 in File S1). To delineate the influence of the resistance on the
projected PrEP effectiveness we evaluate the relative CPF, defined
as the ratios of CPF for scenarios with resistance over scenarios
without resistance:
Influence of Resistance Assumptions on PrEP Impact
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Relative CPF~
CPF (PrEPzresistance)
CPF (PrEP without resistance)
Values of the relative CPF greater than one indicate that the
addition of resistance improves the CPF. The contribution of the
resistance to the PrEP effectiveness is measured by the relative
change in the projected CPF under scenarios with and without
resistance:
Contribution to CPF~1{
CPF (PrEP without resistance)
CPF (PrEPzresistance)
~1{
1
Relative CPF
This metric estimates what fraction of the CPF can be attributed
to the resistance. The contribution of the resistance is positive (i.e.
reduce HIV incidence) when the relative CPF is greater than one.
The influence of resistance parameters on key intervention
outcomes (relative CPF and resistance prevalence after ten years of
PrEP use) is studied in a multivariate sensitivity analysis. Partial
rank correlation coefficients (PRCC) are calculated for each
parameter-outcome pair to evaluate the impact of parameter
variation on the monotonicity of the outcome. The analysis is
based on 10,000 simulations using randomly sampled resistance
parameters and intervention parameters fixed on their baseline
values from Table 1, part C. Additional sensitivity analysis results
are presented in the Supporting Information (see Fig. S3 in File
S1).
Results
Summary of resistance assumptions from the review of
published PrEP models
The resistance parameters used in the published modeling
studies demonstrate enormous variability in assumptions and
uncertainty in values (see Table 2). All the papers (except [19])
include activities to reduce the PrEP use by infected individuals
(positive prescription rejection rate h and drop rate d). However,
some studies assume ‘‘susceptible only’’ access to PrEP (h= 1)
[15,21,26], while others [23,25] explore wide ranges correspond-
ing to interventions with unrestricted access (h= 0) to ‘‘susceptible
only’’ access (h= 1). The rates at which infected PrEP users
acquire resistance (r) also vary substantially across studies. The
range explored in [19,23] suggests that it takes from six months to
indefinitely longer for resistance to develop, while the same time is
estimated at between one and six months in [24,26]. The majority
Figure 2. Public-health impact of 10 years of consistent PrEP use by 50% of the population projected by the model parameterized
with the assumptions extracted from published papers. The outcomes presented are A) the cumulative fraction of prevented infections (CPF);
B) resistance prevalence due to PrEP (RP); C) cumulative fraction of infections in which resistance is transmitted (TRF) and D) resistance contribution to
CPF. The boxplots (median, 2.5th, 25th, 75th, 97.5th percentiles) reflect the variation in impact estimates based on 10,000 simulations (10 per
preselected epidemic set). In D, the contribution of resistance to CPF is calculated as the percentage change in CPF from simulations in which the
resistance is disregarded. Intervention parameters are fixed on their baseline values from Table 1, part C.
doi:10.1371/journal.pone.0080927.g002
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of the studies (all except [19] and [23]) allow for the resistant HIV
to revert back to wild-type HIV when PrEP is not used, with four
of the models differentiating the reversion rates for acquired and
transmitted resistance [15,21,24,26]. Five of the models assume
that the carriers of resistance transmit only resistant HIV
[19,21,23,25,26], while the remaining two allow also for wild-
type HIV to be transmitted with probability of up to 50% and
80%, respectively. All published models agree that the infectious-
ness of the resistance carriers will be decreased due to fitness loss of
the resistant HIV, but the reduced levels explored in each paper
are fundamentally different. Only four of the studies consider the
possibility that PrEP will provide limited protection against
resistant HIV [15,21,24,26].
Contribution of drug resistance to the population-level
PrEP impact
Figure 2 shows the impact of resistance on the predicted PrEP
benefits (ten-year CPF) and PrEP risks (RP and TRF) using
resistance parameters from different modeling studies. The
influence of resistance on the number of infections prevented
varied considerably across studies despite the same behavioral,
epidemic and intervention conditions. The projected ten-year CPF
varied between 32% and 62% (Fig. 2A), the predicted resistance
prevalence among infected individuals varied between from 2% to
44% (Fig. 2B), and the infections in which resistance is transmitted
varied between 1% and 8% (Fig. 2C). The two sets (P1 and P2)
Figure 3. Impact of the relative PrEP efficacy (cr, 0 – no protection, 1 – equal protection) when exposed to drug-resistant compared
to wild type HIV and the relative infectiousness (br, 0 – not infectious, 1 – equally infectious) of individuals infected with drug-
resistant compared to wild-type HIV on the resistance contribution to the cumulative fraction of infections prevented (CPF) over 10
years. A) Contour plots of the relative CPF with all resistance parameters, except cr andbr , fixed on their baseline values from Table 2 (last column).
Values less than one (shaded region) indicate that resistance impacts negatively the estimate of the CPF. Blue dots represent the median value of cr
and brfrom the parameter sets defined in Table 2; and B) Simulations with positive (red) and negative (blue) resistance contributions using resistance
parameters randomly sampled from the ranges in Table 2 (last column).; Relative CPF is calculated as the ratio of the 10-year CPF for scenarios with
resistance over baseline scenario (no resistance).
doi:10.1371/journal.pone.0080927.g003
Figure 4. Partial rank correlation coefficients (PRCC) between resistance-related parameters and intervention outcomes, relative
10-year CPF (green) and resistance prevalence after 10 years (blue) based on 10, 000 simulations (10 per preselected epidemic set).
The intervention parameters are fixed on their baseline values from Table 1, part C. Relative CPF is calculated as the ratio of the 10-year CPF for
scenarios with resistance over baseline scenario (no resistance).
doi:10.1371/journal.pone.0080927.g004
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that produce the most optimistic predictions in terms of CPF
(43%–62%) also predict the largest resistance prevalence (20%–
44%). If the model is parameterized with the set P1 the resistance
has a substantial contribution (a median of 18%) to the PrEP
effectiveness, which translates into up to 11% of the total HIV
infections additionally prevented due to resistance over ten years
(Fig. 2D). In contrast, the model using parameter sets P4–P7
projects only 32%–33% infections prevented over ten years, with a
minimal variation due to the resistance assumptions. Note that the
resistance prevalence due to PrEP with the parameter set P5
remains below 1% in 97.5% of the simulated epidemics, while the
results obtained with set P7 predict approximately the same
reduction in HIV infections over ten years, but a larger proportion
of resistance among HIV-positive individuals (up to 7% in some
simulations). Under the parameterization with P4 resistance still
adds to CPF (its contribution is up to 5%), while the simulations
using P7 show negative contribution of resistance to CPF, i.e.,
actual reduction of CPF by up to 10%.
The magnitude of the resistance contribution (positive or
negative) is limited when stronger restrictions on PrEP use by
HIV positive individuals are imposed. All sets except P1
incorporate restricted access to PrEP (positive prescription
rejection rates h and PrEP drop rates d) for infected individuals,
but the stronger control assumed in the sets P4–P7 (h near 1 and
large d) leads to a substantially smaller number of infected people
who use PrEP, i.e, being at risk of emerging resistance. Another
factor limiting resistance effects is the reversion of the resistant
HIV back to wild-type after the interruption of PrEP use. It is
included in all sets except P1 and P2 (positive t and t1). The faster
reversion assumed in sets P4–P7 implies short persistence of
resistance when PrEP is not used, and smaller influence of the
resistance on the intervention outcomes.
The large uncertainty in the projections with sets P1 and P2 is
driven by the wide range for the average time (1/r) needed to
acquire resistance when infected and using PrEP (between six
months and never), unrestricted or weakly-restricted access to
PrEP by infected individuals, and irreversible resistance status after
PrEP is interrupted. This allows for accumulation of a substantial
number of infected individuals using PrEP who in some scenarios
quickly acquire persistent resistance, while in others may never
develop ADR. Conversely, when the infected users are quickly
removed from PrEP and the reversal of drug resistance back to
wild-type does not take long, the influence of resistance on the
intervention outcomes remains low (sets P4 and P5) under all
epidemic conditions.
When is drug resistance beneficial?
The projections of our model with different parameter sets
suggest that the possibility for the resistance to contribute
positively to PrEP effectiveness (Fig.2D, P1–4) is utilized by two
modeling assumptions: i) the influence of the reduced viral fitness
of the drug-resistant HIV on its ability to be effectively transmitted
and ii) the loss of PrEP protection due to an exposure to drug-
resistant compared to wild-type HIV, which act in opposite
directions. The loss of viral fitness lowers the infectiousness of the
carriers of resistance (relative infectiousnessbr) and indirectly increases
the effectiveness of PrEP, while the reduced PrEP efficacy against
resistant HIV (relative PrEP efficacy cr) decreases the number of
infections prevented due to PrEP, and as a result decreases the
effectiveness of the interventions. Parameter sets, which assume
that the PrEP efficacy is the same against resistant and non-
resistant HIV (cr~1) and that resistance carriers are significantly
less infectious (brƒ0:5), predict positive contribution of the
resistance to CPF (Fig. 2D, P1–P3). A negative resistance
contribution to CPF (Fig. 2D, P5–P7) is observed when a relatively
low PrEP efficacy against resistant HIV (crƒ0:5) is combined with
a small fitness cost of resistance (br§0:5).
We study further the impact the relative infectiousness (br) and
relative PrEP efficacy (cr) on the relative CPF with the rest of the
resistant parameters fixed (Fig.3A) or varied in their ranges from
Table 2 (Fig.3B). This analysis confirms that the resistance is more
likely to be beneficial in terms of CPF if the infectiousness of drug
resistance carriers is substantially reduced (relative infectiousness
below 50%) compared to the wild-type HIV carriers. If PrEP
provides the same protection against resistant and wild-type HIV
(relative efficacy equals one), then resistance always improves the
CPF independently of relative infectiousness of the infected with
resistant HIV. Overall, resistance has negative effects on CPF only
if PrEP is substantially less effective against resistant HIV, and
resistance carriers are almost as infectious as wild-type carriers
(shaded region in Fig. 3A and blue region in Fig. 3B). The perfect
alignment between these regions and the clear separation between
blue and red plots in Fig. 3B suggest that the impact of the
remaining resistance parameters on the relative CPF is negligible.
Therefore, the combination of relative infectiousness and relative efficacy
used in a mathematical model could be a good predictor of
whether the inclusion of resistance increases or reduces the
projected PrEP effectiveness. The median values of the relative
infectiousness and efficacy from the published studies plotted in Fig.3A
are sufficient to correctly predict the direction of resistance
contribution (positive for P1–P4 and negative for P5–P7) when
corresponding parameter sets are used (Fig. 2D).
Sensitivity analysis
The partial rank correlation coefficients (PRCC) between
resistance parameters and intervention outcomes (relative CPF
and resistance prevalence after ten years) are presented in Figure 4.
It clearly confirms the observation from the previous section that
only the relative PrEP efficacy against resistant HIV and relative
infectiousness of the resistance carriers have a strong impact on the
monotonicity of the relative ten-year CPF. The restriction of the
PrEP use by infected individuals and the resistance reversion rate
are among the key factors, negatively correlated with the resistance
prevalence. Not surprisingly, the rate to develop resistance while
infected and using PrEP is the strongest driver of the expected
resistance prevalence and therefore needs to be carefully
monitored when a particular PrEP intervention is rolled out.
Discussion
Possible spread of drug-resistance due to the availability of PrEP
is a major public health concern when deciding to include PrEP in
HIV prevention programs. In this study we simulated and
objectively compared the influence of different resistance assump-
tions on the predicted population-level impact of PrEP. We have
borrowed PrEP resistance profiles from previously published
modeling studies and tested the extracted parameter sets under
identical epidemic conditions and intervention scenarios. This
analytic approach allowed us to assess the impact of each
resistance assumption on intervention outcomes in order to guide
the interpretation of these in further studies. We found that a wide
range of resistance prevalence (from 1% to almost 50%) may be
expected after ten years of PrEP use if 50% effective PrEP is
consistently used by 50% of the population (Fig. 2B). The spread
of resistance may contribute both negatively (up to 10%) or
positively (up to 30%) to the projected PrEP effectiveness,
depending on what resistance parameterization has been used
(Fig. 2D).
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From a public-health perspective our analysis implies that the
influence of resistance should not be neglected. The large impact
projected under scenarios with weak control on the access to PrEP
by infected individuals and slow reversion back to wild-type after
PrEP is interrupted suggests that PrEP users have to be carefully
monitored in future community interventions. Modeling studies
which do not address the emergence of resistance not only
underestimate the risk, but may predict PrEP impact at
significantly different levels compared to analyses in which
resistance is included (up to 30% under some of the extracted
sets of resistance assumptions). Although we are not in a position to
recommend or reject any specific resistance-handling setups, we
would like to point out the critical importance of the way
resistance is incorporated in the modeling studies.
Many different factors should be considered when the
mechanisms of emergence and persistence of drug-resistance due
to PrEP are analyzed. We identified two of them: the decreased
PrEP efficacy against resistant HIV, and the reduction in HIV
fitness (decreased infectiousness of resistance carriers), which in
combination may serve as a predictor if whether drug resistance
will add to the projected PrEP effectiveness (Fig. 3). Although
under no conditions should the spread of resistant HIV be
considered a positive outcome, this result is informative, for the
efforts to resolve the problems with resistance may improve or
reduce the overall impact of the intervention. More empirical data
is needed to obtain better estimates of those parameters for the
promising PrEP candidates.
Several simplifying assumptions, made in the model, may
influence the presented results. For instance, the contribution of
resistance is amplified by the reduced infectiousness of PrEP users
applied in the model. This assumption, incorporated in four of the
published studies [19,21,23,25], is based on the expected lower
viral load of individuals who become infected while using PrEP
(breakthrough infections). Modeling the adherence to PrEP
present additional difficulties because the effects of the inconsistent
PrEP use on the PrEP efficacy and the rate of resistance
emergence is unclear. Our simplifying assumption of perfect
adherence avoids these uncertainties but may overestimate the
projected impact of PrEP. However, it does not affect the
comparison of the extracted sets of resistance assumptions since
we use the resistance rates from the published papers which
correspond to perfect adherence. The epidemic conditions,
intervention assumptions, the structure and complexity of the
model, and the sampling methods of the input parameters used in
our analysis differ from the original studies. Therefore, the results
reported are not comparable to those reported in the previously
published papers and are representative of the extracted sets of
resistance assumptions only.
This analysis presents a novel approach of identifying and
investigating the importance of specific mechanisms and assump-
tions to the impact evaluations based on mathematical models.
Our findings invite extensive communication between modelers
and virologists toward clarifying the set of resistance assumptions
biologically relevant to the PrEP products which are already in use
or may be soon added to the arsenal against HIV. We should
reiterate that our projections are related to resistance due to PrEP
only and do not track resistance from other sources, such as failing
ART. It is possible that the carriers of PrEP resistance may have
increased chance to fail ART when initiated if PrEP and ART
used at the same location share active components. Therefore, the
increasing number of people using PrEP should be closely
monitored and all breakthrough infections should be tested for
drug-resistance. Data on the rates of resistance development,
reversion of resistance, fitness loss of the drug-resistant HIV and
rates of failing ART among those who become infected while
using PrEP is critically needed to improve the accuracy of the
resistance projections obtained through mathematical models.
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